Pelthos Therapeutics Inc.
PTHS NYSE· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$15.20
KIRA · Stoqly’s AI analyst, in plain words
- Pelthos Therapeutics Inc. had $16.8M of revenue in fiscal 2025.
- Its operating margin was −193.1%: of every 100 in sales, about −193 is left after running the business.
- Pelthos Therapeutics Inc. lost $43.3M in fiscal 2025.
- Free cash flow was −$22.7M in fiscal 2025, −135.1% of revenue.
- Pelthos Therapeutics Inc. returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 237.4%.
Market cap
$53.8M
P/E
—
Revenue
$16.8M
Net income
−$43.3M
Free cash flow
−$22.7M
Operating margin
−193.1%
Pelthos Therapeutics Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−257.9%
No. It lost money last year.
Does profit turn into cash?
−135.1%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Pelthos Therapeutics Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 19, 2026
- Legal name
- Pelthos Therapeutics Inc.
- CIK
- 0001919246
Pelthos Therapeutics Inc. · PTHS
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Sales and profit | ||||
| Revenue | — | — | $0.0M | $16.8M |
| Gross margin | — | — | — | 76.3% |
| Operating margin | — | — | — | −193.1% |
| Net income | −$2.5M | −$7.4M | −$8.0M | −$43.3M |
| Net margin | — | — | — | −257.9% |
| Diluted EPS | — | −$5.78 | −$14.27 | −$23.04 |
| Cash | ||||
| Cash from operations | −$1.6M | −$1.0M | −$5.8M | −$22.6M |
| Capital expenditure | — | — | $0.0M | $0.1M |
| Free cash flow | — | — | −$5.8M | −$22.7M |
| FCF margin | — | — | — | −135.1% |
| Share buybacks | — | — | $0.1M | $0.0M |
| Share count change | — | — | −56.3% | 237.4% |
| Debt and strength | ||||
| Cash and short-term investments | $0.1M | $0.1M | $0.5M | $18.0M |
| Shareholders' equity | −$3.7M | −$6.4M | −$2.7M | $38.9M |
| Current ratio | 0.0x | 0.0x | 0.3x | 2.1x |
| Interest coverage | −17.1x | −22.2x | −9.6x | −10.8x |
| Returns and quality | ||||
| Return on equity | — | — | — | −239.5% |
| Piotroski F-score | — | — | — | 4 |
| Altman Z'' | −1,088.3 | −1,375.1 | −102.0 | −1.5 |
Insiders bought, 12 months
$1.0M
1 insider
Insiders sold, 12 months
$0.5M
5 insiders
Of sales under plans
34%
$0.2M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Pelthos Therapeutics Inc. · PTHS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $15.20 a share, the company is worth $53.8M.
Source: SEC EDGAR XBRL filings (CIK 0001919246). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.